ClinicalTrials.govpublic full text
Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC
pancreatic cancer metastatic, brca1, brca2, or palb2 mutation, metastatic pancreatic cancer, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 828491
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.